Abstract
Efforts to develop and refine percutaneous approaches to cardiac valve repair and replacement have advanced rapidly over the past several years, having exceeded even the most optimistic expectations. New innovations have been predominantly directed toward the most frequent form of valvular heart disease (VHD) in the industrialized world; aortic stenosis (AS). Approximately 250,000 transcatheter aortic valve implantation (TAVI) procedures have been done so far addressing this significant medical need.
Because of the predominance of degenerative etiologies, the prevalence of VHD increases markedly in population above the age of 65 years, in particular with regard to severe AS. As the populations of the industrialized countries continue to be older, the need for less invasive and safer methods of treating severe AS will continue to grow.
In this review we provide comprehensive and up-to-date overview of TAVI in current clinical practice. We have also addressed dilemmas and unanswered questions related to TAVI procedures in different groups of patients and highlighted opportunities and trends related to future TAVI implementation.
Keywords: Aortic stenosis, TAVI, future trends, cardiac valve, heart disease, aortic stenosis.
Current Pharmaceutical Design
Title:Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends
Volume: 23 Issue: 31
Author(s): Marko Banovic*, Jozef Bartunek, Serge D. Nikolic, Vladan Vukcevic, Srdjan Aleksandric and Bernard Iung
Affiliation:
- Cardiology Department, University Clinical Center of Serbia, Belgrade,Serbia
Keywords: Aortic stenosis, TAVI, future trends, cardiac valve, heart disease, aortic stenosis.
Abstract: Efforts to develop and refine percutaneous approaches to cardiac valve repair and replacement have advanced rapidly over the past several years, having exceeded even the most optimistic expectations. New innovations have been predominantly directed toward the most frequent form of valvular heart disease (VHD) in the industrialized world; aortic stenosis (AS). Approximately 250,000 transcatheter aortic valve implantation (TAVI) procedures have been done so far addressing this significant medical need.
Because of the predominance of degenerative etiologies, the prevalence of VHD increases markedly in population above the age of 65 years, in particular with regard to severe AS. As the populations of the industrialized countries continue to be older, the need for less invasive and safer methods of treating severe AS will continue to grow.
In this review we provide comprehensive and up-to-date overview of TAVI in current clinical practice. We have also addressed dilemmas and unanswered questions related to TAVI procedures in different groups of patients and highlighted opportunities and trends related to future TAVI implementation.
Export Options
About this article
Cite this article as:
Banovic Marko *, Bartunek Jozef , Nikolic D. Serge , Vukcevic Vladan , Aleksandric Srdjan and Iung Bernard , Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612822666161018162022
DOI https://dx.doi.org/10.2174/1381612822666161018162022 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical and Biological Properties of Phenolics in Wine: Analytical Determinations and Health Benefits
Current Organic Chemistry Phenolic Content in Traditionally Processed Erythrina indica L. Seeds: Antioxidant Potential and Type II Diabetes Related Functionality
Current Nutrition & Food Science Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) The Molecular Concept of Atheromatous Plaques
Current Drug Targets Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Biological Consequences of Dysfunctional HDL
Current Medicinal Chemistry Editorial (Thematic Issue: Targeting Cell Death and Proliferation Receptors in Cancer)
Current Pharmaceutical Design Nitric Oxide Synthase Function in Exercise
Current Enzyme Inhibition Genomics and Natural Products: Role of Bioinformatics and Recent Patents
Recent Patents on Biotechnology Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Cell-free Nucleic Acids as a Non-Invasive Route for Investigating Atherosclerosis
Current Pharmaceutical Design The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations
Current Clinical Pharmacology